Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants
- PMID: 1640282
- DOI: 10.1016/s0022-3476(05)81186-2
Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants
Abstract
Objective: To compare the immunogenicity of three Haemophilus influenzae type b (Hib) conjugate vaccines in infants residing in different geographic areas.
Design: A multicenter, randomized immunogenicity trial with sera assayed in one laboratory without knowledge of vaccine brand status. In Minneapolis and Dallas, infants were vaccinated at 2, 4, and 6 months of age; in St. Louis, infants were vaccinated at 2 and 4 months of age.
Subjects: A convenience sample of 458 infants recruited largely from private pediatric practices.
Measurements and results: At each of the study sites, the respective trends between the anticapsular antibody responses of the infants assigned to the different conjugate vaccine groups were similar. After one or two doses, Hib polysaccharide conjugated to outer membrane protein complex of Neisseria meningitidis (PRP-OMP) was more immunogenic than Hib polysaccharide-tetanus toxoid conjugate (PRP-T), or Hib oligomers conjugated to the mutant diphtheria toxin CRM197 (HbOC) (p less than 0.001). After two doses, PRP-T was more immunogenic than HbOC (p less than or equal to 0.001). After three doses there was no significant difference in the geometric mean antibody concentrations of the three groups, and 88% to 97% of the infants had greater than 1.0 microgram/ml of antibody. The HbOC vaccine elicited a 10-fold lower antibody response after two doses (0.45 micrograms/ml vs 5.9 micrograms/ml) and a threefold lower antibody response after three doses (6.3 micrograms/ml vs 22.9 micrograms/ml) than observed by us previously with a prelicensure lot of this vaccine (p less than 0.001). Because of these low responses, the infants in St. Louis who received two doses of HbOC were revaccinated with unconjugated PRP at a mean age of 8.9 months. This group was immunologically primed, as evidenced by a 10-fold increase in geometric mean antibody concentration after vaccination at an age when unprimed infants do not normally respond to this vaccine.
Conclusions: In infants in three geographic regions, PRP-OMP elicited earlier acquisition of serum antibody than the other two conjugate vaccines; however, after three doses the antibody concentrations of the three groups were not significantly different. The reason for the markedly lower immunogenicity of HbOC vaccine than reported previously is unknown.
Similar articles
-
Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants.JAMA. 1994 Oct 12;272(14):1116-21. JAMA. 1994. PMID: 7933324 Clinical Trial.
-
Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine in infants.Am J Dis Child. 1993 Aug;147(8):832-6. doi: 10.1001/archpedi.1993.02160320034015. Am J Dis Child. 1993. PMID: 8352217 Clinical Trial.
-
Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines.Vaccine. 1993;11 Suppl 1:S46-51. doi: 10.1016/0264-410x(93)90160-y. Vaccine. 1993. PMID: 8447176 Review.
-
Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.JAMA. 1992 Mar 18;267(11):1489-94. JAMA. 1992. PMID: 1538539
-
Haemophilus influenzae type b conjugate vaccines: a review of efficacy data.Pediatr Infect Dis J. 1998 Sep;17(9 Suppl):S117-22. doi: 10.1097/00006454-199809001-00005. Pediatr Infect Dis J. 1998. PMID: 9781743 Review.
Cited by
-
Modeling insights into Haemophilus influenzae type b disease, transmission, and vaccine programs.Emerg Infect Dis. 2012 Jan;18(1):13-20. doi: 10.3201/eid1801.110336. Emerg Infect Dis. 2012. PMID: 22257582 Free PMC article.
-
Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study.J Infect Dis. 2024 Oct 16;230(4):e971-e984. doi: 10.1093/infdis/jiae273. J Infect Dis. 2024. PMID: 38853614 Free PMC article. Clinical Trial.
-
Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in Mali.Am J Trop Med Hyg. 2012 Jun;86(6):1026-31. doi: 10.4269/ajtmh.2012.11-0807. Am J Trop Med Hyg. 2012. PMID: 22665612 Free PMC article.
-
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.Infect Immun. 2005 Jan;73(1):369-77. doi: 10.1128/IAI.73.1.369-377.2005. Infect Immun. 2005. PMID: 15618174 Free PMC article. Clinical Trial.
-
Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new lambda light chain-associated idiotype and the relation between idiotype expression, avidity, and vaccine formulation. The Collaborative Vaccine Study Group.J Clin Invest. 1993 Mar;91(3):788-96. doi: 10.1172/JCI116298. J Clin Invest. 1993. PMID: 8450060 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials